Solana Company Announces Updated SOL Holdings and Industry Leading Staking Yield




Solana Company Announces Updated SOL Holdings and Industry Leading Staking Yield

NEWTOWN, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) — Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”) today announced its updated Solana (“SOL”) token and cash holdings as of Oct. 29 at 12:00 am ET, as well as its current staking performance.

This update reflects the Company’s continued execution of its mission to maximize SOL per share through disciplined execution of its digital asset treasury strategy including capital deployment, active onchain management, and transparent reporting.

As of Oct. 29, the Company and its subsidiaries collectively hold over 2.3 million SOL, which is an increase of roughly 1 million since our last update on Oct. 6. The Company and its subsidiaries also collectively hold in excess of $15 million of cash and stablecoins, which it intends to use to further the digital asset strategy.

For the month of October through October 27^th (the latest complete epoch), the Company’s average gross staking yield was 7.03% APY. This performance was approximately 36 basis points better than the 6.67% APY stake-weighted average of the top 10 validators over that same period. Solana Company’s SOL holdings are primarily staked through institutional-grade validator infrastructure, with rewards automatically restaked to compound returns. This staking yield translates to consistent daily onchain revenue generation while preserving full liquidity and custody of underlying assets.

“Our strategy integrates disciplined capital markets execution with high-performance on–chain yield,” said Cosmo Jiang, General Partner at Pantera Capital and Board Observer at the Company. “HSDT has increased its SOL holdings by roughly 5% in less than a month. Additionally, with a gross staking yield of over 7%, our Solana holdings are compounding and outperforming benchmarks by more than 35 basis points. This consistent alpha demonstrates the strength of our active management mode, which captures both onchain productivity and capital markets efficiency.”

“Institutional engagement with Solana Company has accelerated following key network milestones and ecosystem developments,” said Joseph Chee, Executive Chairman of Solana Company and Chairman of Summer Capital. “We remain focused on transparency and growth, operating at the intersection of capital markets and blockchain innovation. The goal is to develop a compounding vehicle that grows intrinsic value through disciplined capital allocation and long-term alignment with the Solana network’s success.”

Solana remains one of the world’s fastest-growing blockchain networks, processing over 3,500 transactions per second and maintaining approximately 3.7 million daily active wallets. The network is among the leaders in transaction revenue and user adoption, offering an estimated 7% native staking yield, positioning SOL as a financially productive asset for long-term treasuries.

Created in partnership with Pantera Capital and Summer Capital, The Solana Company serves as the market’s dedicated vehicle for institutional participation in the Solana ecosystem. Its approach integrates capital markets access, onchain management, and long-term staking to compound SOL-denominated returns. Through transparent disclosures on asset composition, yield, and performance, the Company provides investors with a structured, regulated channel to capture Solana’s growth.

For additional information, including the latest Chairman’s Note and corporate presentation, please visit https://www.solanacompany.co/investor-relations.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements are statements other than historical facts and include, without limitation, statements regarding the potential for and amount of additional cash proceeds from warrant exercises, the anticipated use of proceeds from the announced Offering, future stockholder approvals, future announcements and priorities, expectations regarding management, corporate governance, market position, business strategies, future financial and operating performance, and other projections or statements of plans and objectives.

These forward-looking statements are based on current expectations, estimates, assumptions, and projections, and involve known and unknown risks, uncertainties, and other factors—many of which are beyond the Company’s control—that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Important factors that may affect actual results include, among others, the Company’s ability to execute its growth strategy; its ability to raise and deploy capital effectively; developments in technology and the competitive landscape; the market performance of SOL; and other risks and uncertainties described under “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2025, and in other subsequent filings with the SEC. These filings are available at www.sec.gov. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

About Solana Company
Solana Company (NASDAQ: HSDT) is a listed digital asset treasury dedicated to acquiring and holding Solana (SOL). Created in partnership with Pantera Capital and Summer Capital, Solana Company’s objective is to maximize SOL per share through strategic use of capital markets and onchain opportunities, offering public market investors direct exposure to Solana’s secular growth.

For more information, please visit www.solanacompany.co or follow us on X (@Solana_Company).

Media Contacts:

Vivian Health Partners with Hallmark to Power Faster, Smarter Hiring




Vivian Health Partners with Hallmark to Power Faster, Smarter Hiring

New integration connects Vivian, the largest healthcare talent marketplace, with Hallmark’s Workforce Intelligence and Enablement Platform—streamlining travel nurse and allied health clinician placements.

SAN FRANCISCO, Oct. 29, 2025 (GLOBE NEWSWIRE) — Vivian Health, the largest online marketplace for healthcare talent serving more than 2.5 million clinicians, and Hallmark Health Care Solutions, Inc., the leader in workforce intelligence and enablement, today announced a strategic partnership designed to transform how agencies and healthcare facilities connect with top-tier clinicians. The collaboration integrates Vivian’s AI-enabled hiring technology into Hallmark’s Flexible Workforce and Total Vendor Management solutions within its Workforce Intelligence and Enablement Platform, enabling seamless submission of travel, per diem and local clinician candidates—including nurses and allied health professionals.

Vivian Health and its proprietary AI Assistant, which is powered by over one million job searches and 2.7 million applications annually, leverages healthcare-specific data, such as licenses and certifications, to match candidates with the right fit across more than 250,000 job opportunities. This integration results in a more streamlined hiring process through intelligent screening, automated profile and packet generation, and one-click submissions—boosting recruiter efficiency, improving conversion rates, and freeing up time to focus on building relationships with clinicians.

“We’re thrilled to extend the power of Vivian’s AI-driven hiring tools into Hallmark’s ecosystem, bringing automation and intelligence to critical workflows that have traditionally been manual and time-consuming,” said Parth Bhakta, CEO of Vivian Health. “This integration enables staffing agencies to operate more efficiently while offering clinicians a faster, more seamless experience from initial interest to final placement.”

The partnership between Vivian Health and Hallmark is a natural fit optimizing the hiring process and helping health systems maintain high-quality care by placing the right talent quickly and efficiently.

“At Hallmark, we’re committed to bringing smarter, more flexible workforce solutions to the healthcare industry,” said Bharat Sundaram, CEO of Hallmark. “Our partnership with Vivian Health is a powerful step forward in advancing our mission to help health systems better match labor supply with demand, reduce overall labor expenses, and maintain quality of care.”

Staffing agencies interested in enabling the integration should reach out to their Hallmark or Vivian representative or contact partnerships@vivian.com.

About Vivian Health:

Vivian Health, an IAC company (NASDAQ: IAC), is the largest online marketplace for healthcare talent, transforming how clinicians find jobs and connect with employers. Featuring intelligent matching, transparent salary information, and the widest selection of opportunities—spanning staff roles, per diem shifts, local contracts, and travel positions—more than 2.5 million healthcare professionals turn to Vivian to find their perfect job opportunity.

Built into its platform, Vivian’s new AI Assistant enables healthcare systems, travel nursing agencies, and allied health agencies to engage with quality candidates and fill critical roles faster than ever before, and with greater efficiency. Vivian is headquartered in San Francisco with offices in New York City. To learn more, visit vivian.com.

About Hallmark

Hallmark is the leader in Workforce Intelligence and Enablement, providing technology for health systems and provider groups nationwide. The platform combines workforce intelligence, flexible workforce management, total workforce vendor management and provider enablement to help health systems optimize labor spend, integrate physician performance and compensation, and improve workforce engagement and retention. 

Serving more than 50 health systems, Hallmark’s technology manages over $10 billion in physician compensation annually, enables sourcing of 25K+ clinicians, and supports over 100K+ users daily. By delivering real-time insights and AI-enabled automation, Hallmark empowers health system leaders to drive sustainable margin improvement while advancing access, quality, and staff well-being. 

Discover why leading health systems trust Hallmark at hallmarkhcs.com and follow on LinkedIn. 

Contact:
Media inquiries can be directed to PR@vivian.com

CMR Surgical Adopts NVIDIA IGX THOR for AI-Powered, Next Generation Surgical Robotics




CMR Surgical Adopts NVIDIA IGX THOR for AI-Powered, Next Generation Surgical Robotics

CMR Surgical Adopts NVIDIA IGX THOR for AI-Powered, Next Generation Surgical Robotics

● Testing to focus on the potential to deliver real-time, AI-powered insights that improve patient outcomes and support continuous learning for surgeons

Cambridge, UK – 29 October 2025, CMR Surgical (‘CMR’), the global surgical robotics business, today announces it is an early adopter of NVIDIA IGXThor as it evaluates its integration into the Versius Surgical Robotic System.

IGX Thor is NVIDIA’s latest and most powerful platform designed for physical AI and robotics, delivering up to 5,581 FP4 TFLOPS of AI compute with 400 GBe of connectivity, offering more compute power, better energy efficiency and awareness compared with previous platforms.

A pioneer in surgical robotic innovation, CMR’s goal is to improve patient outcomes by leveraging its data with AI to deliver insights and recommendations in real time, at the point of care. Ultimately, we aim to enable the data captured from every Versius procedure to improve all surgeries. Working closely with NVIDIA, CMR will evaluate IGX Thor’s AI capabilities for the next-generation of Versius, bringing intelligent surgical support to enhance surgeons’ capabilities and democratise minimally invasive surgery.

Versius captures extensive telematic, video and patient outcome data through its digital ecosystem to deliver meaningful insights to surgeons and hospitals. Today, Versius delivers those insights through the Versius Connect app, Versius Team and Customer dashboards, with the goal of supporting improved surgical care.

Chris Fryer, Chief Technology Officer at CMR Surgical, commented: “Today’s announcement reflects our strategic intent in leveraging the formidable potential of AI and represents a further step forward in our mission to deliver real-time insights that improve outcomes. The goal of AI isn’t to replace surgeons, but to empower them. We’re excited to explore how NVIDIA IGX Thor can revolutionise the AI capabilities within the Versius ecosystem and look forward to continuing to work closely with the NVIDIA team.”

Versius is a unique, versatile and adaptable surgical robot designed to seamlessly and easily integrate into any operating room and hospital workflow. The system has performed c.40,000 surgical cases to date and is being used across a broad range of specialties including urology, general surgery, gynaecology, and thoracic surgery in leading hospitals around the world. Versius can be easily moved between departments, making it suitable for any care setting from low acuity, high-volume cases to the most complex oncological surgical procedures.

Media Contacts: If you wish to see more, please contact CMR Surgical at:
Press Office, CMR Surgical
E pressoffice@cmrsurgical.com

Notes to editors:
The Versius Surgical Robotic System

Versius resets expectations of robotic surgery. Versius fits into virtually any operating room set-up and integrates seamlessly into existing workflows, increasing the likelihood of robotic minimally invasive surgery (MAS). The small, portable and modular design of Versius allows the surgeon to only use the number of arms needed for a given procedure.

Biomimicking the human arm, Versius gives surgeons the choice of optimised port placement alongside the dexterity and accuracy of small fully-wristed instruments. With 3D HD vision, easy-to adopt instrument control and a choice of ergonomic working positions, the open surgeon console has the potential to reduce stress and fatigue and allows for clear communication with the surgical team. By thinking laparoscopically and operating robotically with Versius, patients, surgeons and healthcare professionals can all benefit from the value that robotic MAS brings.

But it’s more than just a robot. Versius captures meaningful data with its wider digital ecosystem to support a surgeon’s continuous learning. Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.

About CMR Surgical Limited

CMR Surgical (CMR) is a global medical devices company dedicated to transforming surgery with Versius, a next-generation surgical robot.

Headquartered in Cambridge, United Kingdom, CMR is committed to working with surgeons, surgical teams and hospital partners, to provide an optimal tool to make robotic minimally invasive surgery universally accessible and affordable. With Versius, we are on a mission to redefine the surgical robotics market with practical, innovative technology and data that can improve surgical care.

Founded in 2014, CMR Surgical is a private limited company backed by an international shareholder base.

Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients




Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients

October 29, 2025

• 3-Year data from the largest global trial to date using Class I, Level A iFR in heart attack patients shows treating additional stenoses in the same procedure showed no significant difference in major outcomes compared with waiting for follow-up
• Additional results from the ILIAS ANOCA study highlight the sustained benefits of physiology-guided assessment and tailored medical therapy for patients with angina and no obstructive coronary arteries

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced late-breaking results from the iMODERN trial (Instantaneous wave-free Ratio Guided Multivessel Revascularisation During PCI for Acute Myocardial Infarction) at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 conference, the world’s leading meeting for interventional cardiology. The study compared immediate versus delayed treatment of additional narrowed arteries in heart attack patients to determine whether treating all blockages in one procedure is as safe and effective as waiting for a follow-up procedure. The study compared immediate versus deferred treatment of additional narrowed arteries in heart attack patients to determine whether treating all blockages in a single procedure is superior to waiting for a follow-up procedure – a key question, since many patients have multiple diseased arteries and the optimal timing for complete treatment remains uncertain.

In today’s practice, when patients suffer a serious type of heart attack (STEMI), cardiologists urgently open the blocked artery causing the attack. But many of these patients also have disease in other arteries. Often these additional narrowed arteries are not treated right away, either due to time restraints, patient stability, resource constraints or because they stay unnoticed. They may be treated later in a separate hospital stay or not at all, leaving uncertainty about the best timing and approach.

The new findings show that patients can safely have additional arteries treated immediately during the first procedure to treat the acute event, rather than during a later second intervention. By confirming the safety of extending Class I, Level A-recommended iFR to non-stable patients, the results offer physicians the opportunity to complete treatment in one session, without compromising long-term outcomes. The iMODERN trial is the largest study to date testing iFR* in the acute heart attack setting, expanding the evidence base for a tool already strongly recommended (Class I, Level A) in stable patients.

The findings are published in The New England Journal of Medicine (NEJM), underscoring its global scientific significance and impact on cardiology practice.

“These results address one of the longest-standing questions in interventional cardiology,” said Prof. Niels van Royen, co-principal investigator, Radboud University Medical Center, The Netherlands. “Measuring and eventually treating additional arteries can be performed during the first procedure or during a staged procedure. That means cardiologists can feel confident offering patients a complete solution in one sitting when it’s appropriate.”

The iMODERN study enrolled 1,146 patients across 41 hospitals in 14 countries directly addressed this question. Patients were randomly assigned to one of two treatment strategies: either immediate physiology-guided treatment of additional narrowed arteries during the first procedure using instantaneous wave-free ratio (iFR), or staged treatment guided by cardiac Magnetic Resonance Imaging (MRI) carried out within four days to six weeks after the heart attack. The study’s main endpoint combined three outcomes: death, another heart attack, or hospitalization for heart failure over three years. After three years of follow-up, the trial found no significant difference in major outcomes – including death, repeat heart attack, or hospitalization for heart failure – between the two approaches. By confirming that both approaches are backed by solid evidence, the trial offers patients more certainty and more personalized care.

“Flexibility is critical in real-world practice,” added Prof. Dr. Robin Nijveldt, co-principal investigator, at Radboud University Medical Center, in the Netherlands. “Some patients may benefit from immediate treatment, while others are better served by waiting. iMODERN is a pragmatic study that shows that an immediate intervention is not necessarily better than waiting, if patients are offered a CMR to evaluate the need for a second intervention, giving physicians the evidence they need to tailor decisions to each patient.”

“These results complement current international guideline recommendations (Class I recommendation, Level A evidence) for complete revascularization in STEMI,” said Dr. Darshan Doshi, practicing interventional cardiologist and Head of Medical & Clinical at Philips Image-Guided Therapy Devices. “By integrating physiological assessment, iMODERN’s evidence demonstrates that cardiologists can follow these findings for full revascularization while also tailoring treatment to each vessel’s true ischemic relevance.”

Complementary evidence from ILIAS ANOCA
In related findings presented at the same conference, the ILIAS ANOCA (Inclusive Invasive Physiological Assessment in Angina Syndromes – Angina with No Obstructive Coronary Artery Disease) study further demonstrated the value of physiology-guided decision-making — this time in patients with angina and no obstructive coronary arteries (ANOCA). The ILIAS ANOCA study evaluated the impact of coronary function testing (CFT) in patients whose coronary arteries appear unobstructed on angiography but who continue to experience angina. Conducted across five cardiac centers in the Netherlands and Germany (n=153), the investigator-initiated, randomized, blinded-arm controlled trial compared standard care with CFT-guided medical therapy using Philips Doppler FloWire and FloMap systems.

The study found that ad-hoc CFT followed by tailored therapy significantly improved patient-reported angina symptoms and quality of life at six months, with a mean 9.4-point gain in the Seattle Angina Questionnaire summary score (95% CI 3.9–14.9; p=0.001). There were no procedure-related complications or major adverse cardiac events. These results confirm and extend the earlier CorMiCA findings, supporting CFT as a Class I, Level A recommendation in ANOCA patients and demonstrating the potential of Philips Doppler technology to guide individualized treatment strategies safely and effectively. The 12-month results presented on October 26^th demonstrate the sustained benefits of CFT-guided care.

iFR and MRI technology
Philips physiology solutions – including its instantaneous wave-free ratio (iFR) pressure wires and software – were used to guide immediate treatment decisions in the trial. Philips also provides advanced cardiac MRI technology, which guided the delayed strategy. By enabling both the invasive and non-invasive approaches evaluated in iMODERN, Philips supported the generation of robust evidence to help guide clinical practice worldwide.

* iFR (instantaneous wave-free ratio) is a minimally invasive way to measure blood pressure through the coronary arteries, helping physicians decide which blockages require stenting.

For further information, please contact:

Joost Maltha
Philips Global External Relations
Tel.: +31 6 1055816
E-mail: joost.maltha@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

• Philips iFR technology

Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test to diagnose dengue




Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test to diagnose dengue

• New dengue antigen test delivers high clinical sensitivity and specificity, as well as inclusivity for all four dengue virus serotypes, helps clinicians confidently distinguish dengue from other acute fever-causing illnesses.
• Full automation facilitates medium to high throughput and enables improvement of lab efficiency and test traceability, while reducing the risk of human error.
• Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks.¹

Basel, 29 October 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE mark for its Elecsys® Dengue Ag test – a high-throughput, fully automated immunoassay to be used as an aid in the diagnosis of an acute dengue virus infection. This milestone promises to set a new standard for efficiency and reliability in tackling the growing global challenge of dengue fever.

Dengue fever is the most common mosquito-borne viral illness in the world. In 2024, more cases of dengue were recorded than ever before in a 12-month period, affecting over 100 countries on all continents. During 2024, ongoing transmission, combined with an unexpected spike in dengue cases, resulted in a historic high of over 14.6 million cases and more than 12,000 dengue-related deaths. Over the past 50 years, the spread of the disease has accelerated, posing a significant global health threat as half of the world’s population now lives in areas at risk of infection.²

The symptoms of dengue aren’t unique, so doctors often struggle to distinguish it from other fever-causing illnesses, such as chikungunya or yellow fever. This is why early and accurate diagnosis is critical so that patients can be managed in a timely manner to prevent severe complications.

“Dengue’s rapid worldwide spread has elevated it to a serious global burden, placing a significant strain on healthcare resources,” said Matt Sause, CEO of Roche Diagnostics. “Roche is committed to supporting the global response to the rise of infectious diseases such as dengue. With our novel Elecsys Dengue antigen test, we enable healthcare systems to diagnose dengue more reliably and efficiently.”

Recognising the value of diagnostics, the World Health Organization (WHO) has developed an “Essential Diagnostics List” which includes in-vitro diagnostic solutions that should be accessible to all countries to increase timely and life-saving diagnoses. Dengue virus NS1 antigen, along with other biomarkers, is included in the WHO essential IVD list.³

About the Elecsys Dengue virus antigen immunoassay
The Elecsys Dengue Ag is an in-vitro diagnostic immunoassay for the qualitative detection of the NS1 antigen of the dengue virus in human serum and plasma, a key marker of acute infection during the first days of illness. It is intended for use on Roche’s fully automated cobas® e immunoassay analysers: cobas e 801 systems and cobas e 402 platforms – a widely used platform with an extensive installed base in laboratories worldwide.

The test has been shown to reliably detect NS1 antigen for all four dengue virus serotypes – DENV-1, DENV-2, DENV-3, and DENV-4.⁴ In clinical studies, it demonstrated 94.90% (CI: 91.44–97.26%) sensitivity in PCR-confirmed positive samples and 99.96% (CI: 99.79–100%) relative specificity in a large cohort of healthy blood donors.

Key benefits of the Elecsys Dengue Ag test include:

Reliable and Fast Results: The Elecsys Dengue Ag test has a turnaround time of 18 minutes. It is designed for use on Roche’s automated cobas e immunoassay analyzers with a throughput from 120 to up to 300 tests/hour. This ensures reliable results for effective patient management during outbreaks and supports surveillance efforts in both endemic and non-endemic settings.

Enhanced Efficiency and Traceability: The automated nature of the Elecsys and cobas instruments improves laboratory consolidation, workflow, and traceability, reducing manual activities and the potential for human error.

Comprehensive response across the entire patient journey: The Elecsys Dengue Panel, which includes the Elecsys Dengue Ag test, alongside the Elecsys Dengue IgM test and Elecsys Dengue IgG test that will be subsequently launched, is designed to cover all key serological biomarkers for dengue diagnosis. By addressing NS1 for acute infection, IgM for recent exposure, and IgG for long-term immunity, the panel equips clinicians with the tools to diagnose dengue accurately at every stage of the disease.

About Dengue
Dengue is a mosquito-borne disease transmitted to humans through the bite of infected female mosquitoes, primarily of the Aedes aegypti species. While most people have no symptoms or only mild, self-limiting ones (fever, body aches, headache), a small percentage of cases can progress to severe dengue, which is life-threatening and involves complications like bleeding and organ impairment.

The global incidence of dengue is rising sharply due to climate change expanding the mosquito’s range, putting nearly half the world’s population at risk.⁵ Children, the elderly, individuals with weakened immune systems, and those with underlying conditions are at higher risk of developing severe dengue. Close monitoring and fluid management are crucial to prevent severe complications.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] World Health Organization, Dengue Factsheet, August 2025, available at URL: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue
[2] Phillips ML. Dengue reborn: widespread resurgence of a resilient vector. Environ Health Perspect. 2008 Sep;116(9):A382-8. doi: 10.1289/ehp.116-a382. PMID: 18795135; PMCID: PMC2535648. https://doi.org/10.1289%2Fehp.116-a382eClinicalMedicine. Dengue as a growing global health concern. EClinicalMedicine. 2024 Nov 25;77:102975. doi: 10.1016/j.eclinm.2024.102975. PMID: 39649133; PMCID: PMC11625016.
[3] WHO Model List of Essential In Vitro Diagnostics, September 2025, available at URL: https://edl.who-healthtechnologies.org/
[4] Elecsys® Dengue Ag method sheet, V1.0 2025-06.
[5] World Health Organization, August 2025 ,https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue
https://www.who.int/news/item/03-10-2024-who-launches-global-strategic-plan-to-fight-rising-dengue-and-other-aedes-borne-arboviral-diseases

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Attachment

• Media Release Dengue Antigen CE Mark English

Addex Increases Issued Share Capital to Create Treasury Shares




Addex Increases Issued Share Capital to Create Treasury Shares

Ad Hoc Announcement Pursuant to Art. 53 LR

Geneva, Switzerland, October 29, 2025 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that 34,300,000 new registered shares at a nominal value of CHF 0.01 have been issued and fully subscribed by Addex Pharma S.A, its 100% wholly-owned subsidiary. The new shares, issued from the Company’s capital band, are listed on the SIX Swiss Exchange. The transaction has been executed to provide Addex with additional future financing flexibility. The issued share capital increased to CHF 2,186,544.96 representing 218,654,496 issued shares at a nominal value of CHF 0.01 each, whilst the number of outstanding shares remains unchanged.

About Addex Therapeutics

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex’s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders.

Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com

  
Contacts: 

Addex Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Bio Usawa Takes Strategic Step into Europe with New Subsidiary in Frankfurt, Germany




Bio Usawa Takes Strategic Step into Europe with New Subsidiary in Frankfurt, Germany

KIGALI, Rwanda and FRANKFURT, Germany and SAN FRANCISCO, Oct. 29, 2025 (GLOBE NEWSWIRE) — Bio Usawa Biotechnology Ltd (Rwanda) proudly announces the establishment of its new European subsidiary, Bio Usawa Biotech Europe GmbH, headquartered in Frankfurt, Germany.

This strategic development marks a significant milestone in Bio Usawa’s mission to bridge African innovation with international research, regulatory, and commercial networks.

Bio Usawa selected Frankfurt for its reputation as one of Europe’s foremost life sciences and pharmaceutical hubs, providing access to leading scientific expertise, strong global partnerships, and a vibrant biotechnology ecosystem.

The new European subsidiary will strengthen Bio Usawa’s ability to collaborate with institutions and companies that share its vision of developing and delivering advanced biologic therapies that reach patients faster and more affordably.

“Establishing Bio Usawa Biotech Europe GmbH represents an important step in Bio Usawa’s journey,” said Dr. Menghis Bairu, CEO and President of Bio Usawa. “We are building a company that connects continents – advancing science from Africa to the world and bringing global expertise back to Africa. Our aim is to develop biotechnology solutions that are innovative, high-quality, and accessible to all.”

The Frankfurt-based entity will serve as Bio Usawa’s European anchor for partnerships, regulatory engagement, and scientific collaboration, reinforcing the company’s role as a bridge between Africa and the global biotechnology community.

As part of its broader vision, Bio Usawa is helping transform Africa’s “brain drain” into “brain gain” — attracting talented scientists and innovators from Africa and friends of Africa across the diaspora who are eager to contribute to the continent’s rapidly evolving biotechnology landscape. By fostering cross-continental collaboration and knowledge exchange, Bio Usawa is demonstrating that scientific excellence transcends borders.

About Bio Usawa, Inc

Bio Usawa is Rwanda’s pioneering biotech company that is dedicated to developing, manufacturing, and commercializing high-quality, affordable biosimilars for patients in Africa. Through partnerships with governments, research institutions, and healthcare providers, Bio Usawa is advancing biotechnology innovation in Africa, by Africans, for Africa – and beyond.

Media Contact:

Daniel Levine
Levine Media Group
+1 510-280-5405
danny@levinemediagroup.com

14-year-old Combines Origami and Physics to Engineer Foldable Structures for Disaster Relief Shelters; Wins $25,000 Top Award at Thermo Fisher Scientific Junior Innovators Challenge




14-year-old Combines Origami and Physics to Engineer Foldable Structures for Disaster Relief Shelters; Wins $25,000 Top Award at Thermo Fisher Scientific Junior Innovators Challenge

Young innovators recognized with $100K for STEM research advancing science and tackling global challenges

WASHINGTON, Oct. 28, 2025 (GLOBE NEWSWIRE) — Thermo Fisher Scientific and Society for Science today announced the winners of the Thermo Fisher Scientific Junior Innovators Challenge (Thermo Fisher JIC), the nation’s leading middle school science, technology, engineering and math (STEM) competition. Miles Wu, 14, from New York City, won the $25,000 Thermo Fisher Scientific ASCEND (Aspiring Scientists Cultivating Exciting New Discoveries) Award, the top prize in the competition.

Exploring the power of origami-inspired engineering, Miles tested 54 variations of the Miura-ori fold, a geometric pattern that packs flat and unfolds in one smooth motion. His research revealed that designs with smaller panels and steeper angles weren’t just stronger, they were remarkably resilient. Using dumbbells, he discovered they could support more than 9,000 times their own weight. Miles hopes to apply these insights to develop strong, lightweight shelters that can be rapidly deployed in areas affected by natural disasters.

The Thermo Fisher JIC, a program of Society for Science, reaches 60,000 middle school students nationwide, inspiring them to pursue their STEM interests and explore exciting college and career paths. The 30 finalists, who were selected from nearly 2,000 applicants representing 48 states, American Samoa, Guam, the Northern Mariana Islands and Puerto Rico; are counted among the nation’s brightest students, with several, including Miles, collectively receiving more than $100,000 at tonight’s award ceremony in Washington, D.C. Winners were chosen by a panel of distinguished scientists, engineers and educators and the finalists’ schools also received a $1,000 grant to support STEM programming.

Each of the 30 finalists participated in team challenges in addition to being judged on their research projects. The challenges incorporated project-based learning to test critical thinking, communication, creativity and collaboration skills across a variety of STEM fields. They included coding with Micro:Bit processors to address climate change, conducting environmental forensics to solve a public health issue, exploring physics and engineering through building chain reactions and applying biomimicry in the design of a blue crab hydraulic claw.

“Miles’ remarkable blend of scientific creativity, leadership and collaboration highlights the type of talent Society for Science is proud to support,” said Maya Ajmera, President & CEO, Society for Science and Executive Publisher, Science News. “I look forward to seeing the innovative ideas he will contribute in the future.”

The other top winners included:

Akhil Nagori, 15, from Santa Clara, CA, won the $10,000 Broadcom Coding with Commitment ® Award for combining STEM learning with coding to solve a community problem they care about that aligns with the 17 Sustainable Development Goal of the United Nations. For his project, Akhil worked as part of a team to develop an inexpensive pair of glasses that can translate text to speech, to help visually impaired students have wide access to reading materials.

Peter Fernández Dulay, 15 from Jacksonville, FL, won the $10,000 DoD STEM Talent Award for demonstrating excellence in science, technology, engineering or math; along with the leadership and technical skills necessary to excel in the 21^st Century STEM workforce and build a better community for tomorrow. Peter had four image-generating AI platforms make images of five different types of scientists and found that because the AI tools learned from limited data, the tools perpetuated stereotypes about male bias in science.

Evann Sun, 14, from Santa Clara, CA, won The Lemelson Foundation Award for Invention of $10,000, which is given to a young inventor creating promising product-based solutions to real-world problems. Evann worked as part of a team to develop a pair of glasses that can translate text to speech, to help visually impaired students have wide access to reading materials.

Camila Isabel Gonzalez-Thompson, 14, from Ponce, Puerto Rico, won the $10,000 Robert Wood Johnson Foundation Award for Health Advancement, which recognizes the student whose work and performance shows the most promise in health-related fields and demonstrates an understanding of the many social factors that affect health. Camila examined blood samples from Puerto Ricans for antibodies to dengue virus, and showed that the virus is endemic to Puerto Rico, helping public health officials target interventions.

Thermo Fisher’s sponsorship of the Junior Innovators Challenge reflects the company’s longstanding commitment to broadening access to STEM education. For decades, it has invested in school-based STEM programs, and employees across the company volunteer thousands of hours each year to support education initiatives around the world.

“This year’s winners embody the ingenuity and perseverance that drive progress in STEM and improve lives,” said Dr. Karen Nelson, Chief Scientific Officer, Thermo Fisher Scientific. “We are honored to celebrate these remarkable young thinkers as they advance their scientific research and inspire students of all backgrounds to explore the world through STEM.”

In addition to the top prizes, Thermo Fisher and the Society announced first- and second-place winners in each STEM category (science, technology, engineering and math), as well as the competition’s Team Award.

First- and second-place STEM Award winners demonstrated exceptional skill and promise in science, technology, engineering or math. First-place winners received $3,500 and second-place winners received $2,500 to support their choice of a STEM summer camp experience in the U.S.

Science Award:

• First place: Pranshi Mehta, Austin, TX, “Machine Learning-Mediated Computational Modeling of FK506-Binding Protein 12 (FKBP12)-Enhanced CAR T-Cell Therapy for Targeted Glioblastoma Treatment”
• Second place: Christine Wang, San Jose, CA, “Peel To Purify: An Innovative Fruit Waste-Based Solution for Contaminated Water Treatment”

Technology Award:

• First place: Caden Terence Pohlkamp, Friendswood, TX, “Is More Green Better? Does Littoral Vegetation Enhance Habitat Suitability of Local Retention Ponds?”
• Second place: Alice Feng, Fresno, CA, “Transforming Waste Into Value: The Impact of Grape Pomace Variety and Extraction Parameters on Grape Seed Oil Yield and Physicochemical Properties”

Engineering Award:

• First place: Brady Ryan Sage, Rapid City, SD, “Optimizing Driver Flight Distance and Accuracy”
• Second place: Luca McGill, Tucson AZ, “ALTO-CO₂: Low-Cost Drone-Based Atmospheric Carbon Dioxide Monitoring Across Urban, Suburban, and Rural Areas in Southern Arizona”

Mathematics Award:

• First place: Tobias Lam, Austin, TX, “The Effect of Nintendo’s NES Tetris Theme Music and 28 Hertz High Beta-Frequency Binaural Beats on a 233 Hertz Carrier on Attention Span”
• Second place: Siddharth Sudharshan Vazhkudai, Cedar Park, TX, “AIM-BASE: AI-Integrated Model To Predict the Energy Consumption of Extra-Terrestrial Colonies”

Team Award, sponsored by Teaching Institute for Excellence in STEM (TIES): Each member of the Finals Week challenge team that best demonstrates an ability to work together and solve problems through shared decision making, communication and scientific and engineering collaboration received a $200 science supply company gift card to support their interests in STEM. The winning team members are Lia Camil González, Tobias Lam, Yookta Pandit, Sam Daniel Solhpour and Bhavya Uppalapati.

Thermo Fisher Scientific Leadership Award: Bestowed upon one finalist, this award recognizes the student elected by their peers to speak on behalf of their Thermo Fisher JIC class at the Awards Ceremony. The Class Speaker demonstrates the collegiality and spirited leadership that has earned the collective esteem of the class and united them around common goals. The 2025 awardee is Akhil Nagori from Santa Clara, CA.

Media Kit: https://www.societyforscience.org/thermo-fisher-jic-2025-media-kit

About Society for Science
Society for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its STEM outreach programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire. Learn more at www.societyforscience.org and follow us on Facebook, Twitter/X, and Instagram.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contact Information:
Gayle Kansagor
Society for Science
gkansagor@societyforscience.org

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/300ae6b7-28df-4b51-a50e-962939dffb47

Canadian Red Cross opens appeal to help people impacted by Hurricane Melissa




Canadian Red Cross opens appeal to help people impacted by Hurricane Melissa

OTTAWA, Oct. 28, 2025 (GLOBE NEWSWIRE) — The Canadian Red Cross has launched the Hurricane Melissa Appeal to help those impacted by the hurricane in the Caribbean.

The Red Cross is working to get help to people in affected areas as quickly as possible.

Money raised will enable the Red Cross to provide immediate relief, support recovery efforts, and resilience and preparedness and capacity strengthening activities for future events. The activities and areas impacted may evolve based on emerging needs and compounding future events.

People in Canada wishing to make a donation can do so online at redcross.ca or by calling 1-800-418-1111.

Additional Resources
@redcrosscanada.bsky.social | facebook.com/CanadianRedCross | redcross.ca/blog  
Red Cross donor inquiries: WeCare@redcross.ca or 1-800-418-1111

About the Canadian Red Cross
Here in Canada and overseas, the Red Cross stands ready to help people before, during and after a disaster. As a member of the International Red Cross and Red Crescent Movement – which is made up of the International Federation of Red Cross and Red Crescent Societies, the International Committee of the Red Cross and 191 national Red Cross and Red Crescent societies – the Canadian Red Cross is dedicated to helping people and communities in Canada and around the world in times of need and supporting them in strengthening their resilience.

MEDIA CONTACTS
English Media: 1-877-599-9602 media@redcross.ca  
French Media: 1-888-418-9111 communication@croixrouge.ca

Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year




Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year

MINNEAPOLIS and BRISBANE, Australia, Oct. 28, 2025 (GLOBE NEWSWIRE) — Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced one-year clinical outcomes for the DurAVR^® Transcatheter Heart Valve (THV) in symptomatic severe aortic stenosis patients with small aortic annuli (aortic annulus area 396 + 37 mm²). The DurAVR^® THV System demonstrated single digit mean gradients and large effective orifice areas (EOAs), no moderate or severe paravalvular leaks and no valve related mortality at one year, with low prosthesis-patient mismatch at 30 days.

One-year Results Highlights

• DurAVR^® THV delivered a favorable hemodynamic profile sustained to one-year, with an EOA of 2.1 + 0.2 cm² and a mean pressure gradient (MPG) of 8.6 + 2.6 mmHg. 
• At one-year, clinical safety outcomes were positive with no valve related mortality and no moderate or severe paravalvular leak (PVL).
• At 30-days, prosthesis-patient mismatch* was just 1.5%, compared with 11.2% to 35.3%¹ for current commercial devices, highlighting a meaningful reduction in a key predictor of valve failure and disease progression.

“With small annuli patients, even minor hemodynamic inefficiencies can limit long-term outcomes, which is why optimising physiologic flow is so critical. The latest results we are seeing with the balloon-expandable DurAVR^® valve are impressive, showing restoration of laminar flow, favorable hemodynamics sustained to one year, predictable deployment and a high level of procedural success across a variety of anatomies, which is exactly what we need for this patient population,” commented Dr. Rishi Puri, MD, PhD, Coronary and Structural Interventional Cardiologist at the Cleveland Clinic.

The pooled cohort included 65 patients with small aortic annuli implanted with the DurAVR^® THV from the ongoing EMBARK Study and US Early Feasibility Study (EFS).

The encouraging clinical outcomes observed to date in over 100 patients implanted with the DurAVR^® THV will be further validated in the Company’s recently initiated global pivotal trial (the “PARADIGM Trial”). The PARADIGM Trial (ClinicalTrials.gov ID NCT07194265) is a prospective, randomized controlled trial (RCT) which will evaluate the safety and effectiveness of the DurAVR^® THV compared to commercially available transcatheter aortic valve replacements (TAVRs) in the treatment of severe aortic stenosis.

^{*Prosthesis‐patient mismatch (PPM) happens when a prosthetic valve, after being implanted, doesn’t have a large enough opening (EOA) to accommodate the patient’s blood flow needs, based on their body size. The result is higher than expected gradients. PPM affects a significant proportion of transcatheter aortic valve (TAVR) patients, particularly patients with a small aortic annulus and has been associated with impaired long-term survival following surgical aortic valve replacement (SAVR)².}

^{1. Herrmann HC, Mehran R, Blackman DJ, Bailey S, Möllmann H, Abdel-Wahab M, Ben Ali W, Mahoney PD, Ruge H, Wood DA, Bleiziffer S, Ramlawi B, Gada H, Petronio AS, Resor CD, Merhi W, Garcia Del Blanco B, Attizzani GF, Batchelor WB, Gillam LD, Guerrero M, Rogers T, Rovin JD, Szerlip M, Whisenant B, Deeb GM, Grubb KJ, Padang R, Fan MT, Althouse AD, Tchétché D; SMART Trial Investigators. Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus. N Engl J Med. 2024 Jun 6;390(21):1959-1971. doi: 10.1056/NEJMoa2312573. Epub 2024 Apr 7. PMID: 38587261.}

^{2. Ferrara J, Theron A, Porto A, Morera P, Luporsi P, Jaussaud N, Gariboldi V, Collart F, Cuisset T, Deharo P. Prosthesis-Patient Mismatch in Small Aortic Annuli: Self-Expandable vs. Balloon-Expandable Transcatheter Aortic Valve Replacement. J Clin Med. 2022 Apr 1;11(7):1959. doi: 10.3390/jcm11071959. PMID: 35407567; PMCID: PMC8999619.}

About Anteris

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris’ lead product, the DurAVR^® Transcatheter Heart Valve (THV), was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR^® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR^® THV is made using a single piece of molded ADAPT^® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT^® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR^® THV System is comprised of the DurAVR^® valve, the ADAPT^® tissue, and the balloon-expandable ComASUR^® Delivery System.

Forward-Looking Statements

This announcement contains forward-looking statements, including statements regarding the further validation of results in the PARADIGM Trial. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2024 that was filed with the SEC and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.